Immunohistochemical Analysis of P-53 and Ki-67 Expression in Surface Epithelial Ovarian Tumor
Authors/Creators
- 1. Junior Resident, Department of Pathology, BRD Medical College, Gorakhpur, Uttar Pradesh, India
- 2. Professor, Department of Pathology, BRD Medical College, Gorakhpur, Uttar Pradesh, India
- 3. Professor & Head of The Department, Department of Pathology, BRD Medical College, Gorakhpur, Uttar Pradesh, India
- 4. Associate Professor, Department of OBS & Gynae, BRD Medical College, Gorakhpur, Uttar Pradesh, India
- 5. Assistant Professor, Department of Pathology, BRD Medical College, Gorakhpur, Uttar Pradesh, India
Description
Background: Ovarian cancer is the sixth most common female cancer worldwide and third most common gynaecological cancer. Surface epithelial tumors of ovary (SEOT) are commonest among of all ovarian tumors and their malignant forms represents about 90% of malignant ovarian tumors. It is well known for its late presentation at advanced stage. Recently molecular and proliferative markers including p-53 and Ki-67 have emerged as promising adjuvant diagnostic tool for early diagnosis and identification of their biological behavior. Over expression of p-53 and Ki-67 has been claimed to be a marker of aggressiveness in SEOT. Aim And Objectives: To study and interpret the expression pattern of p-53 and Ki-67 in benign, borderline and malignant SEOT and assessing early aggressiveness and tumour progression of SEOT. Material & Methods: The study was performed on 100 consecutive resected specimen of SEOT received in pathology department over a period of one year. 10% Formalin fixed, paraffin embedded tissue sections were stained by haematoxylin & Eosin stain for histological analysis and immunohistochemical staining was performed using monoclonal antibodies against p-53 and Ki-67 in all the cases. The expression pattern of p-53 and Ki-67 was studied in terms of proportion score in p-53 and Labelling index (LI) in Ki-67. Result: In the study of 100 cases of SEOT benign lesions (49%) followed by malignant lesions (37%) and borderline lesions (14%). The expression of p-53 was less in benign (7/49, 14.3%) than borderline (8/14, 57.1%) and malignant tumors (33/37, 89.2%). The Ki-67 expression was more in malignant (35/37, 94.6%) than borderline (13/14, 92.8%) and benign tumors (5/49, 10.2%). A positive correlation were observed in p-53 and Ki-67 expression with tumour grade and FIGO stage. Their co-expression was seen in 46% of cases that was statistically significant (p- value < 0.000012). Conclusion: p-53 and Ki-67 expression correlate with worse prognosis in SEOTs and are useful adjuvant marker for understanding of biological behavior of these tumors which helps in guiding appropriate management and therapy in these patient.
Abstract (English)
Background: Ovarian cancer is the sixth most common female cancer worldwide and third most common gynaecological cancer. Surface epithelial tumors of ovary (SEOT) are commonest among of all ovarian tumors and their malignant forms represents about 90% of malignant ovarian tumors. It is well known for its late presentation at advanced stage. Recently molecular and proliferative markers including p-53 and Ki-67 have emerged as promising adjuvant diagnostic tool for early diagnosis and identification of their biological behavior. Over expression of p-53 and Ki-67 has been claimed to be a marker of aggressiveness in SEOT. Aim And Objectives: To study and interpret the expression pattern of p-53 and Ki-67 in benign, borderline and malignant SEOT and assessing early aggressiveness and tumour progression of SEOT. Material & Methods: The study was performed on 100 consecutive resected specimen of SEOT received in pathology department over a period of one year. 10% Formalin fixed, paraffin embedded tissue sections were stained by haematoxylin & Eosin stain for histological analysis and immunohistochemical staining was performed using monoclonal antibodies against p-53 and Ki-67 in all the cases. The expression pattern of p-53 and Ki-67 was studied in terms of proportion score in p-53 and Labelling index (LI) in Ki-67. Result: In the study of 100 cases of SEOT benign lesions (49%) followed by malignant lesions (37%) and borderline lesions (14%). The expression of p-53 was less in benign (7/49, 14.3%) than borderline (8/14, 57.1%) and malignant tumors (33/37, 89.2%). The Ki-67 expression was more in malignant (35/37, 94.6%) than borderline (13/14, 92.8%) and benign tumors (5/49, 10.2%). A positive correlation were observed in p-53 and Ki-67 expression with tumour grade and FIGO stage. Their co-expression was seen in 46% of cases that was statistically significant (p- value < 0.000012). Conclusion: p-53 and Ki-67 expression correlate with worse prognosis in SEOTs and are useful adjuvant marker for understanding of biological behavior of these tumors which helps in guiding appropriate management and therapy in these patient.
Files
IJPCR,Vol15,Issue5,Article227.pdf
Files
(3.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:8c71ef41fdac999abdba5ba647bd0bd5
|
3.2 MB | Preview Download |
Additional details
Dates
- Accepted
-
2023-04-24
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue5,Article227.pdf
- Development Status
- Active
References
- 1. Sreeja T. T., Chandrasekhar S, S. Lokesh Rao Magar. et al. A Study on Expression of P-53 in Surface Epithelial Ovarian Tumours. Indian Journal of Mednodent and Allied Sciences, February 2015;3(1): 18-25. 2. Swarnalatha P, Reddy SR, Chaitanya B. Study of histomorphological spectrum of ovarian neoplasms: an institutional perspective. International Journal of Advances in Medicine. September October 2019; 6(5):1563- 1566 3. Kaur, Ashmeet & Faujdar et al. Histomorphological Spectrum of Bone Tumors in A Tertiary Care Hospital.Annals of Pathology and Laboratory Medicine, 2018; A559-566. 4. Jaffrey T. Quirk et al. risk factors for invasive epithelial ovarian carcinoma by histological subtype. 2004;3. 5. Ferlay et al – risk factors and age distribution in Ireland. 1995 – 2007. 6. Jeffray SD Russell P, Robert KJ. Surface epithelial tumors In Robert kurman J Blausteins pathology of female genital tract, fifth edition, 2002; 791 – 881. 7. Clement P.B., & Young R.H. Ovarian surface epithelial – stromal Tumors. In: Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH. (eds). Sternberg's Diagnostic surgical pathology 5th edition, Lippincot Williams and wilkins USA. 2010;2: 2278 8. Robbins & Cortan pathologic basis of disease 10th edition, volume 2: 1017 9. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Human Pathol. 1985 Jan; 16(1):28-34 10. Dr. C. Aparna. "P-53 over Expression in Ovarian Neoplasms - An Immuno Histochemical Study." IOSR Journal of Dental and Medical Sciences (IOSRJDMS). Feb. 2015; 14(2):Ver. II: 24 -27. 11. Iggo R, Gatter K, Bartek J, et al Increased expression of mutant forms of p-53 oncogene in primary lung cancer. Lancet. 1990; 335: 675- 679. 12. Nesrin Gursan et al P-53, Bcl- 2, Ki67, status in benign borderline, Malignant ovarian surface epithelial neoplasm. Eurasian Journal of Medicine. April 2009; 41. 13. Li LT, Jiang G., Chen Q, Zheng JN. Ki-67 is a promising molecular target in the diagnosis of cancer (Review). Molecular Medicine Reports. 11.3. 2015: 1566-72 14. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1and MIB3) detect proliferating cells in microwave processed formalin fixed paraffin sections. J Pathol. 1992; 168; 357 – 63. 15. Gursan N, Sipal S, Calik M, Gundogdu. P-53, Bcl-2, Ki-67 Li (labeling index) status in benign, proliferative and malignant ovarian surface epithelial neoplasms. Eurasian J Med. 2009; 41: 10 – 4. 16. Skilling JS, Sood A, Niemann T et al. An abundance of p-53 null mutation in ovarian carcinoma. Oncogene 1996; 13: 117 -123. 17. Mohapatra I et al. Int J Repord contracept Obster Gynecol. 2021 Mar; 10(3): 1005-1010 18. Scully RE. International Histological Classification of Tumours: Histological Typing of Ovarian Tumours. 2nd edition Heidelberg: Springer- Verlag. 1998. 19. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstetrical & Gynecological survey. 1972 Nov 1;27(11):751-68. 20. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011 Jun;474 (7353):609. 21. Naik PS, Deshmukh S, Khandeparkar SG, Joshi A, Babanagare S, PotdarJ, et al. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study. J Midlife Health. 2015; 6:178-83. 22. Yusra Abdulkhaliq Qasim et al.; Saudi J. Pathol. Microiol.; Mar 2017;2(3): 52-59. 23. Dr Abhilash Singh et al JMSCR. April 2021;09(04). 24. Saleem, Shauib & Hamid, Elaf. p-53 expression in ovarian tumors: (an immunohistochemical study). Annals of the College of medicine, Mosul. 2012; 38: 73-79. 10. 25. Tiwari Ranjan Kumar, Saha Kaushik, Mukhopadhyay Debasis, Datta Chhanda, Chatterjee Uttara, GhoshTarun Kumar, Evaluation of preoperative Serum Levels of CA 125 and expression of p-53 in ovarian neoplasm: A prospective Clinicopathological study in a tertiary care hospital. The Journal of Obstetrics and Gynecology of India. March- April 2016; 66(2): 107-114. 26. Abbasi F, Esmaili A, Yekta Z, Saffarifard A. Expression of p-53 in ovarian epithelial tumors and its correlation with histopathological parameters. J Ayub Med Coll Abbottabad. 2016 Jan – Mar; 28 (1):3- 6. 27. Singh M, Khan L, Kamthan A. Immunohistochemical Expression of Ki-67 and p-53 in Surface Epithelial Ovarian Tumour. J Evid Based Med Health, May 03, 2021; 50:18(18). 28. Razak Amanullah NA, Poothiode U, Vilas iniamma L, Expression of p-53in epithelial ovarian tumors. Indian J Patho Microbiol. 2020; 63:235-240 29. Mahadevappa A, Krishna SM, Vimala G. Diagnostic and Prognostic Significance of Ki-67 immunohistochemical Expression In Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017 Feb; 11(2): EC08-EC12. 30. Chakdoufi S., Mamoune E. M., Brahim E. M., & Anas, G. A. Postoperative (Pressure) Alopecia on Head Rest Fixation Pointes Area, Following Intracranial Removal of Meningioma. A Rare but Disturbing Complication to Consider. Journal of Medical Research and Health Sciences, 2023; 6(3): 2480–2083.